A drug used alone or with other anticancer drugs to treat adults with certain types of acute myeloid leukemia, mast cell leukemia, or systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Midostaurin blocks certain proteins, which may help keep cancer cells from growing and may kill them. It may also prevent the growth of new blood vessels that tumors need to grow. Midostaurin is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called N-benzoyl-staurosporine, PKC412, and Rydapt.
Are you looking for or in search of FDA approved “sacituzumab govitecan-hziy for injection in India”? “Medicant Healthcare” a registered pharmacy firm in India deals in both brand name as well as generic name Drugs / medicine approved for Breast Cancer. Need Access of sacituzumab govitecan-hziy injection, get in touch with our healthcare professional.
Midostaurin, sold under the brand name Rydapt & Tauritmo both by Novartis, is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus.
The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. Midostaurin is approved to treat:
Acute myeloid leukemia (AML). It is used with cytarabine and daunorubicin hydrochloride in newly diagnosed adults whose cancer has a mutation in the FLT3 gene.
Aggressive systemic mastocytosis, systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia in adults.